Tone mix
Week by week 48 weeks
Share of Humacyte, Inc. Common Stock's 124 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Jan 26, 2026 · tone -100Benchmark Cuts Humacyte (NASDAQ:HUMA) Price Target to $10.00-139
- Week of Apr 6, 2026 · tone +100Humacyte FY2026 EPS Estimate Increased by HC Wainwright+99
- Week of Jun 15, 2026 · tone +100Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting+92
- Week of Aug 4, 2025 · tone 0Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025-85
- Week of Jun 9, 2025 · tone +100D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)+72
- Week of Oct 12, 2026 · tone +98Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals+70
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Humacyte, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 2 | +100 |
| Last 30 sessions | 4 | +74 |
| Last 90 sessions | 31 | +12 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletHumacyte's ATEV Shows Phase 3 Benefits In Women, Supports Planned FDA Label ExpansionPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Humacyte's ATEV Shows Phase 3 Benefits In Women, Supports Planned FDA Label Expansion | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletHumacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months SoonerPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
1 headline, average tone +98: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletHumacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by HospitalsPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 5, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletHumacyte, Inc. (NASDAQ:HUMA) Stock Has Average Price Target of $6.54 According to AnalystsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Humacyte, Inc. (NASDAQ:HUMA) Stock Has Average Price Target of $6.54 According to Analysts | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, September 16, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletHead to Head Review: Humacyte (NASDAQ:HUMA) & uniQure (NASDAQ:QURE)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Head to Head Review: Humacyte (NASDAQ:HUMA) & uniQure (NASDAQ:QURE) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Humacyte, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.